Compugen (NASDAQ:CGEN) Upgraded by Wall Street Zen to Buy Rating

Compugen (NASDAQ:CGEN) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. HC Wainwright initiated coverage on Compugen in a research report on Wednesday, January 7th. They set a “buy” rating and a $4.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $4.00.

Compugen Stock Up 1.5%

Compugen stock opened at $2.08 on Friday. Compugen has a 52 week low of $1.13 and a 52 week high of $2.38. The company has a 50 day moving average price of $1.84 and a 200 day moving average price of $1.67.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. Compugen had a return on equity of 55.68% and a net margin of 48.57%.The firm had revenue of $67.33 million during the quarter, compared to analyst estimates of $14.30 million. Research analysts predict that Compugen will post -0.03 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CGEN. Bank Hapoalim BM acquired a new stake in Compugen during the fourth quarter worth about $37,000. Security National Bank of Sioux City Iowa IA bought a new stake in Compugen in the fourth quarter valued at $38,000. Franklin Resources Inc. bought a new stake in shares of Compugen in the 2nd quarter worth about $56,000. Osaic Holdings Inc. grew its stake in Compugen by 346.0% during the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after buying an additional 34,045 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in Compugen during the 4th quarter valued at $84,000. 12.22% of the stock is currently owned by institutional investors and hedge funds.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.